Testing a new blood test to improve prostate cancer risk assessment
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing a new blood test (Proclarix) to see if it can better predict prostate cancer risk in men who are already scheduled for an MRI and prostate biopsy. The goal is to improve how doctors decide who needs a biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men aged 45 to 80 years old
- Scheduled for a prostate MRI and biopsy as part of standard care at Kantonsspital Aarau
- No prostate treatments (such as surgery, freezing, ultrasound, or radiation) in the last 5 years
- No active urinary tract infection
- Not currently taking 5-alpha reductase inhibitors (a type of medication for prostate enlargement)
- MRI must be done at Kantonsspital Aarau
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test, ClarityDX Prostate, to see if it can help doctors better decide who needs a biopsy. It is for men who have been referred to a urologist because there is a suspicion of prostate cancer but who have not been diagnosed yet.
This study is testing an approach to find prostate cancer earlier in men who may be at higher risk. If you fit the criteria, you may get an mpMRI scan before undergoing a prostate biopsy to check for cancer.
This study checks whether a detailed MRI method can help find prostate cancer earlier in people considered high risk. You may be asked to get an MRI and help the team see if it works well as a screening test.
This trial tests whether repeat MRI scans can help monitor suspicious prostate areas and avoid unnecessary biopsies. It aims to improve detection of significant prostate cancer while reducing invasive procedures.
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
This study is testing a new approach to prostate biopsy that takes samples from around a suspicious area seen on MRI. It aims to see if this method can better detect prostate cancer compared to standard biopsy.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.